Ovarian Reserve
Conditions
Keywords
Endometrioma, Estradiol valerate + dienogest, Dienogest, Ovarian reserve
Brief summary
Progesterone resistance in endometriosis is a known fact. The progestin derivatives used in endometriosis cause decidualization and atrophy of ectopic foci. Moreover, they inhibit neo-angiogenesis, provide suppress expansile/destructive growth facilitated by matrix metalloproteinases, and implantation of ectopic foci. The effect of drugs containing the estrogen-progesterone combination is mainly based on the inhibition of ovulation, decidualization and atrophy of ectopic foci. In estrogen-progesterone mechanism, it is known that estrogen has a progesterone receptor-enhancing effect, which may make progesterone more potent. Based on this, the investigators hypothesized that estrogen added to progesterone could lead to a further reduction in endometrioma size by various mechanisms which probably include the increased progesterone sensitivity in endometriosis. In addition, the investigators hypothesized that this therapy can alleviate the destructive effect of endometriomas on the ovarian reserve.
Interventions
The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
Sponsors
Kocaeli Derince Education and Research Hospital
Suleymaniye Birth And Women's Health Education And Research Hospital
Bagcilar Training and Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Study Group: At least one endometrioma greater than 3 cm, between 18-40 years of age, without surgical indication at the time of diagnosis, occasionally and intermittently controlled pain with NSAIDs or no pain symptom 2. Control Group: Patients with reproductive age without any ovarian cysts
Exclusion criteria
* suspicion of malignancy, irregular mentrual period, endocrine diseases, drug intake that may affect ovarian reserve in the last 6 months (i.e GnRH agonists), previous ovarian surgery, AMH levels under 2 ng/ml.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ovarian reserve | up to 24 months | The investigators evaluate serum anti-Müllerian hormone (AMH) level(ng/mL) using commercial elisa kits and antral follicle count (number) using ultrasonography. The patients with higher ovarian reserve represent a better outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endometrioma Size | up to 24 months | The investigators evaluate endometrioma size (centimeter) using ultrasonography. |
| Pain Score | up to 24 months | Vas score (minimum score:0 and maximum score:10). The patients with lower pain scores represent a better outcome. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactTolga Karacan, M.D
Outcome results
None listed